Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 11/20 | 0.49 |
| ▸ | MGAM | O43451 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 3/20 | 0.48 |
| ▸ | SI | P14410 | 3/20 | 0.48 |
| ▸ | MGAM2 | Q2M2H8 | 3/20 | 0.48 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | PTGES | O14684 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8521769 | 0.85 | MGAM (0.43) | DHODHMGAMGAASIMGAM2 | |
| SCHEMBL7471192 | 0.84 | DHODH (0.45) | DHODHMGAMGAASIMGAM2 | |
| SCHEMBL5203705 | 0.82 | DHODH (0.47) | DHODHMGAMGAASIMGAM2 | |
| SCHEMBL7465458 | 0.81 | MGAM (0.48) | DHODHMGAMGAASIMGAM2 | |
| SCHEMBL5201195 | 0.80 | MGAM (0.72) | MGAMGAASIMGAM2 | |
| SCHEMBL7464040 | 0.79 | HTT (0.42) | DHODHMGAMGAASIMGAM2 | |
| SCHEMBL6687964 | 0.78 | GRIN2B (0.60) | DHODHMGAMGAASIMGAM2 | |
| SCHEMBL7463314 | 0.78 | GRIN2B (0.41) | DHODHMGAMGAASIMGAM2 | |
| SCHEMBL5202010 | 0.76 | CBFB (0.58) | DHODHMGAMGAASIMGAM2 | |
| SCHEMBL5202985 | 0.76 | ADORA2B (0.49) | ADORA2BPARP1PTGESJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1210336-B1 | SUBSTITUTED BENZIMIDAZOLES AS NON-NUCLEOSIDE INHIBITORS OF REVERSE TRANSCRIPTASE | US HEALTH (US) | 2007-04-25 | — | — | EP | disclosed |
| US-6894068-B2 | Substituted benzimidazoles as non-nucleoside inhibitors of reverse transcriptase | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2005-05-17 | — | — | US | disclosed |
| US-20030191160-A1 | Substituted benzimidazoles as non-nucleoside inhibitors of reverse transcriptase | MICHEJDA CHRISTOPHER J (US) | 2003-10-09 | — | — | US | disclosed |
| EP-0963371-B1 | SUBSTITUTED BENZIMIDAZOLES AS NON-NUCLEOSIDE INHIBITORS OF REVERSE TRANSCRIPTASE | US GOV HEALTH & HUMAN SERV (US) | 2003-05-02 | — | — | EP | disclosed |
| EP-1210336-A1 | SUBSTITUTED BENZIMIDAZOLES AS NON-NUCLEOSIDE INHIBITORS OF REVERSE TRANSCRIPTASE | THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services (US) | 2002-06-05 | — | — | EP | disclosed |
| US-6369235-B1 | INHIBITORS OF HIV REVERSE TRANSCRIPTION FOR TREATMENT OF AIDS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2002-04-09 | — | — | US | disclosed |
| WO-2001014343-A1 | SUBSTITUTED BENZIMIDAZOLES AS NON-NUCLEOSIDE INHIBITORS OF REVERSE TRANSCRIPTASE | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2001-03-01 | — | — | WO | disclosed |
| EP-0963371-A1 | SUBSTITUTED BENZIMIDAZOLES AS NON-NUCLEOSIDE INHIBITORS OF REVERSE TRANSCRIPTASE | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-12-15 | — | — | EP | disclosed |
| WO-1998037072-A1 | SUBSTITUTED BENZIMIDAZOLES AS NON-NUCLEOSIDE INHIBITORS OF REVERSE TRANSCRIPTASE | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191160-A1 | Substituted benzimidazoles as non-nucleoside inhibitors of reverse transcriptase | SAMHD1, DUT, TYMP | DHODH 145/4885MGAM 1525/4885GAA 236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.